BCL2 and cancer: Anti-apoptotic inhibitors such as A-1331852 (BCL-xL selective), ABT-199 (BCL-2 selective), S63845 (MCL-1 selective) among others that are now evaluated in the clinic, can be used as single agents or especially in combination with other therapies to enhance cancer elimination7.